LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

Search

Charles River Laboratories International Inc

Closed

Sector Healthcare

174.92 2.22

Overview

Share price change

24h

Current

Min

168.9

Max

175.53

Key metrics

By Trading Economics

Income

-284M

-214M

Sales

-7.2M

1B

P/E

Sector Avg

921.684

72.392

EPS

2.66

Profit margin

-21.32

Employees

18,700

EBITDA

-296M

-86M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+3.85 upside

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

566M

9B

Previous open

172.7

Previous close

174.92

Technical Score

By Trading Central

Confidence

Bullish Evidence

Charles River Laboratories International Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Aug 2024, 10:30 UTC

Top News

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

23 Mar 2024, 13:00 UTC

Top News

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street -- WSJ

Peer Comparison

Price change

Charles River Laboratories International Inc Forecast

Price Target

By TipRanks

3.85% upside

12 Months Forecast

Average 177.62 USD  3.85%

High 190 USD

Low 165 USD

Based on 14 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

1

Buy

13

Hold

0

Sell

Technical Score

By Trading Central

166.715 / 175.12Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.